Lymphomas

John Burke MD and Brad S. Kahl MD review data from key studies in non-Hodgkin’s lymphomas chronic lymphocytic leukemia small lymphocytic lymphoma and Hodgkin’s lymphoma presented at the 2015 American Society of Hematology Annual Meeting.

Share

Program Content

Activities

  • TEDDI-R With Ibrutinib in CNS Lymphoma
    Phase I Study: Dose-Adjusted TEDDI-R With Ibrutinib in Primary CNS Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2015

    Expires: December 06, 2016

  • Ibrutinib vs Temsirolimus in MCL
    MCL3001 (RAY): Ibrutinib vs Temsirolimus in Previously Treated MCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 09, 2015

    Expires: December 07, 2016

  • Ibrutinib + Rituximab in FL
    Ibrutinib Plus Rituximab in Treatment-Naive Patients With Follicular Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 10, 2015

    Expires: December 08, 2016

  • S1106: R-Bendamustine vs R-HyperCVAD in MCL
    S1106: R-Bendamustine vs R-HyperCVAD Induction Therapy Followed by ASCT in MCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2015

    Expires: December 09, 2016

  • NCI 9177: DA-EPOCH-R in BL
    NCI 9177: Risk-Adapted DA-EPOCH-R in Adults With Burkitt Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 11, 2015

    Expires: December 09, 2016

  • RESONATE-2: Ibrutinib in CLL
    Phase III RESONATE-2: Frontline Ibrutinib vs Chlorambucil in Elderly Patients With CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2015

    Expires: December 10, 2016

  • Outcomes After KI Discontinuation in CLL
    Outcomes of CLL Patients Treated With Alternate Kinase Inhibitors Following Ibrutinib or Idelalisib Discontinuation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2015

    Expires: December 10, 2016

  • CALGB 50604: PET-Guided Treatment in HL
    Phase II CALGB 50604: Choosing Chemo/Radiotherapy by PET Status in Hodgkin’s Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2015

    Expires: December 10, 2016

  • PYRAMID: VR-CHOP in DLBCL
    PYRAMID: Frontline R-CHOP ± Bortezomib in Non-GCB DLBCL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 12, 2015

    Expires: December 10, 2016

  • KEYNOTE-013: Pembrolizumab in Previously Treated cHL
    KEYNOTE-013: Pembrolizumab in Classical Hodgkin’s Lymphoma After Brentuximab Vedotin Failure
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2015

    Expires: December 12, 2016

  • Venetoclax in R/R del(17p) CLL
    Venetoclax Monotherapy in R/R CLL With del(17p)
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 14, 2015

    Expires: December 12, 2016

  • ACP-196 in R/R CLL
    ACE-CL-001: Investigation of ACP-196, a Second-Generation BTK Inhibitor, in R/R CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2015

    Expires: December 13, 2016

  • BRESHAP Promising in R/R cHL
    Brentuximab Vedotin + ESHAP in R/R Classical Hodgkin’s Lymphoma
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 15, 2015

    Expires: December 13, 2016

  • Venetoclax + Rituximab for R/R CLL
    Venetoclax + Rituximab in Relapsed/Refractory CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 16, 2015

    Expires: December 14, 2016

  • Study 115: IDELA + BR for R/R CLL
    Idelalisib ± Bendamustine/Rituximab in Relapsed/Refractory CLL
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 17, 2015

    Expires: December 15, 2016

  • Downloadable Slideset
    Lymphomas
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: January 25, 2016

    Expires: January 23, 2017

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Millennium Takeda

Seagen